During the past decade, decreasing the attrition rate of drug development candidates reaching the market has become one of the major challenges in pharmaceutical research and drug development (R&D). To facilitate the decision-making process, and to increase the probability of rapidly finding and developing high-quality compounds, a variety of multiparametric guidelines, also known as rules and ligand efficiency (LE) metrics, have been developed. However, what are the 'best' descriptors and how far can we simplify these drug-likeness prediction tools in terms of the numerous, complex properties that they relate to?
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drudis.2018.01.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!